GILD Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

GILD fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 57.8% below our estimate of its fair value

Earnings are forecast to grow 40.65% per year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

Profit margins (0.4%) are lower than last year (21.5%)

Dividend of 3.33% is not well covered by earnings

+ 1 more risk

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Analyst Price Target

Consensus Narrative from 26 Analysts

Innovative Therapies And Global Expansion Power Dynamic Revenue Growth In Biotech

Key Takeaways Expansion in HIV and oncology sectors can significantly boost revenue with innovative treatments and market penetration. Cost management and strategic product mix improvements are poised to enhance profit margins and support earnings growth.

View narrative

US$98.34

6.1% undervalued

1.95%

Revenue growth p.a.

Updated

Gilead Sciences, Inc. Competitors

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$120.8b

Amgen

NasdaqGS:AMGN

US$148.2b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$83.8b

Seagen

NasdaqGS:SGEN

US$43.2b

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share Price	US$92.38
52 Week High	US$98.90
52 Week Low	US$62.07
Beta	0.20
1 Month Change	-4.79%
3 Month Change	11.09%
1 Year Change	11.18%
3 Year Change	29.73%
5 Year Change	40.65%
Change since IPO	14,498.33%

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Shareholder Returns

	GILD	US Biotechs	US Market
7D	0.9%	-0.8%	-0.2%
1Y	11.2%	6.0%	28.8%

Return vs Industry: GILD exceeded the US Biotechs industry which returned 6% over the past year.

Return vs Market: GILD underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	3.3%
Biotechs Industry Average Movement	10.3%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GILD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	18,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market cap	US$115.08b
Earnings (TTM)	US$126.00m
Revenue (TTM)	US$28.30b

913.7x

P/E Ratio

4.1x

P/S Ratio

Is GILD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILD income statement (TTM)
Revenue	US$28.30b
Cost of Revenue	US$6.28b
Gross Profit	US$22.02b
Other Expenses	US$21.89b
Earnings	US$126.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 11, 2025

Earnings per share (EPS)	0.10
Gross Margin	77.80%
Net Profit Margin	0.45%
Debt/Equity Ratio	126.4%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

3,027%

Payout Ratio

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

When do you need to buy GILD by to receive an upcoming dividend?
Gilead Sciences dividend dates
Ex Dividend Date	Dec 13 2024
Dividend Pay Date	Dec 30 2024
Days until Ex dividend	1 day
Days until Dividend pay date	18 days

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

GILD Stock Overview

Rewards

Risk Analysis

Innovative Therapies And Global Expansion Power Dynamic Revenue Growth In Biotech

Gilead Sciences, Inc. Competitors

NasdaqGS:VRTX

US$120.8b

NasdaqGS:AMGN

US$148.2b

NasdaqGS:REGN

US$83.8b

NasdaqGS:SGEN

US$43.2b

Price History & Performance

Recent News & Updates

Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition

Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH

Chief Financial Officer exercised options and sold US$5.5m worth of stock

Upcoming dividend of US$0.77 per share

Consensus EPS estimates fall by 36%

Chief Medical Officer recently sold US$1.7m worth of stock

Recent updates

Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition

Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH

Chief Financial Officer exercised options and sold US$5.5m worth of stock

Upcoming dividend of US$0.77 per share

Consensus EPS estimates fall by 36%

Chief Medical Officer recently sold US$1.7m worth of stock

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Price target increased by 7.6% to US$94.62

We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Consensus EPS estimates fall by 31%, revenue upgraded

Third quarter dividend of US$0.77 announced

Chief Medical Officer notifies of intention to sell stock

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Upcoming dividend of US$0.77 per share

Gilead Sciences: Buy This Bargain Before It's Gone

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Shareholder Returns

Price Volatility